Abelacimab for Prevention of Venous Thromboembolism
Authors:
- Peter VerhammePVPeter Verhamme
- B. Alexander YiBYB. Alexander Yi
- Annelise SegersASAnnelise Segers
- Janeen SalterJSJaneen Salter
- Daniel BloomfieldDBDaniel Bloomfield
- Harry R. BüllerHBHarry R. Büller
- Gary E. RaskobGRGary E. Raskob
- Jeffrey I. WeitzJWJeffrey I. Weitz
Top Cited Papers
- 12 August 2021
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 385 (7) , 609-617
Abstract
The role of factor XI in the pathogenesis of postoperative venous thromboembolism is uncertain. Abelacimab is a monoclonal antibody that binds to factor XI and locks it in the zymogen (inactive precursor) conformation. In this open-label, parallel-group trial, we randomly assigned 412 patients who were undergoing total knee arthroplasty to receive one of three regimens of abelacimab (30 mg, 75 mg, or 150 mg) administered postoperatively in a single intravenous dose or to receive 40 mg of enoxaparin administered subcutaneously once daily. The primary efficacy outcome was venous thromboembolism, detected by mandatory venography of the leg involved in the operation or objective confirmation of symptomatic events. The principal safety outcome was a composite of major or clinically relevant nonmajor bleeding up to 30 days after surgery. Venous thromboembolism occurred in 13 of 102 patients (13%) in the 30-mg abelacimab group, 5 of 99 patients (5%) in the 75-mg abelacimab group, and 4 of 98 patients (4%) in the 150-mg abelacimab group, as compared with 22 of 101 patients (22%) in the enoxaparin group. The 30-mg abelacimab regimen was noninferior to enoxaparin, and the 75-mg and 150-mg abelacimab regimens were superior to enoxaparin (P<0.001). Bleeding occurred in 2%, 2%, and none of the patients in the 30-mg, 75-mg, and 150-mg abelacimab groups, respectively, and in none of the patients in the enoxaparin group. This trial showed that factor XI is important for the development of postoperative venous thromboembolism. Factor XI inhibition with a single intravenous dose of abelacimab after total knee arthroplasty was effective for the prevention of venous thromboembolism and was associated with a low risk of bleeding. (Funded by Anthos Therapeutics; ANT-005 TKA EudraCT number, 2019-003756-37.)Keywords
Funding Information
- Anthos Therapeutics Inc
This publication has 10 references indexed in Scilit:
- Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee ArthroplastyJAMA, 2020
- MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humansBlood, 2019
- Factor XI Antisense Oligonucleotide for Prevention of Venous ThrombosisNew England Journal of Medicine, 2015
- Congenital Factor XI Deficiency: An UpdateSeminars in Thrombosis and Hemostasis, 2013
- Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosisThrombosis and Haemostasis, 2011
- A dose‐ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplastyJournal of Thrombosis and Haemostasis, 2010
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patientsJournal of Thrombosis and Haemostasis, 2009
- Triggers, targets and treatments for thrombosisNature, 2008
- Defective thrombus formation in mice lacking coagulation factor XIIJournal of Experimental Medicine, 2005
- Prevention of Venous ThromboembolismChest, 2004